Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$29.54−1.08 (-3.53%)
Close on Nov 13, 2026Market cap $1.16BP/E –Yield –
Alto Neuroscience cash
Cash and short-term investments held at the end of each period.
Alto Neuroscience's cash was $319.34M at Sep 30, 2026. For fiscal 2025 it was $176.48M, up 4.6% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $176.48M | +4.6% |
| FY2024 | Dec 31, 2024 | $168.73M | +104.4% |
| FY2023 | Dec 31, 2023 | $82.55M | +70.8% |
| FY2022 | Dec 31, 2022 | $48.34M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $319.34M | +130.9% |
| Q2 FY2026 | Jun 30, 2026 | $243.73M | +64.6% |
| Q1 FY2026 | Mar 31, 2026 | $263.76M | +63.6% |
| Q4 FY2025 | Dec 31, 2025 | $176.48M | +4.6% |
| Q3 FY2025 | Sep 30, 2025 | $138.32M | -24.1% |
| Q2 FY2025 | Jun 30, 2025 | $148.09M | -23.5% |
| Q1 FY2025 | Mar 31, 2025 | $161.25M | -21.7% |
| Q4 FY2024 | Dec 31, 2024 | $168.73M | +104.4% |
| Q3 FY2024 | Sep 30, 2024 | $182.20M | +255.3% |
| Q2 FY2024 | Jun 30, 2024 | $193.62M | +228.0% |
| Q1 FY2024 | Mar 31, 2024 | $205.90M | +213.0% |
| Q4 FY2023 | Dec 31, 2023 | $82.55M | +70.8% |
| Q3 FY2023 | Sep 30, 2023 | $51.29M | – |
| Q2 FY2023 | Jun 30, 2023 | $59.03M | – |
| Q1 FY2023 | Mar 31, 2023 | $65.78M | – |
| Q4 FY2022 | Dec 31, 2022 | $48.34M | – |
See a number that looks wrong?